# LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

> **NCT06090162** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Swiss Cancer Institute** · enrollment: 64 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma, B Cell

## Interventions

- **DIAGNOSTIC_TEST:** ctDNA detection

## Key facts

- **NCT ID:** NCT06090162
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090162, "LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06090162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*